IPP Bureau
Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
By IPP Bureau - December 18, 2023
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lupin receives tentative USFDA approval for Sitagliptin Tablets
By IPP Bureau - December 18, 2023
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Zydus receives final approval from the USFDA for Lacosamide Tablets
By IPP Bureau - December 18, 2023
Lacosamide is indicated to treat partial-onset seizures
Ami Organics inks agreement with Fermion for two additional APIs
By IPP Bureau - December 18, 2023
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
By IPP Bureau - December 18, 2023
10+ emerging markets, Japan & ANZ transition in final phase
Briefs: Torrent Pharmaceuticals and Laurus Synthesis
By IPP Bureau - December 17, 2023
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg
By IPP Bureau - December 17, 2023
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
By IPP Bureau - December 17, 2023
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Fischer Chemic to acquire Time Medical Internaitonal Ventures India
By IPP Bureau - December 17, 2023
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Biocon Biologics recognized as an Asia IP Elite for 2023
By IPP Bureau - December 17, 2023
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Lupin receives USFDA approval for Allopurinol Tablets
By IPP Bureau - December 17, 2023
The product will be manufactured at Lupin's Pithampur facility in India
Panacea Biotec launches EasyFourPol in India
By IPP Bureau - December 17, 2023
Receives registration of Valganciclovir powder for oral solution in Germany
Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
By IPP Bureau - December 17, 2023
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Cipla to further invest Rs. 42 crore in GoApptiv
By IPP Bureau - December 17, 2023
Expands patient reach to remotest towns by furthering investment in GoApptiv
Lupin Diagnostics opens new laboratory in Chennai
By IPP Bureau - December 17, 2023
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
